Iris Manifestations in Inadequately Treated Chronic Recurrent Vogt-Koyanagi-Harada Disease

Win, May Zun Aung

doi:10.1080/09273948.2020.1870701

Cited by 4 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very few cases have been reported in the literature of patients with VKH disease presenting with bilateral iris depigmentation and hypotony. [ 3 4 5 ] All these reported cases were inadequately treated for the disease in the acute phase. The case we reported was also not diagnosed as VKH previously and was never treated with oral steroids and immunosuppressants.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bilateral Iris depigmentation, transillumination defects and hypotony in Vogt–Koyanagi–Harada disease

Garg

Das²,

Bhattacharjee³

et al. 2022

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…As the iris root is more aggressively involved in inflammation, the depigmentation begins peripherally. [ 5 ]…”

Section: Discussionmentioning

confidence: 99%

Bilateral Iris depigmentation, transillumination defects and hypotony in Vogt–Koyanagi–Harada disease

Garg

Das²,

Bhattacharjee³

et al. 2022

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

“…Systemic symptoms include tinnitus, hearing loss, vertigo, meningismus, vitiligo, and poliosis ( O’keefe and Rao, 2017 ). A recent study suggests that delayed diagnosis and inadequate treatment lead to iris deterioration in patients with chronic recurrent disease ( Chee and Win, 2021 ). VKH disease generally affects young women and is the leading cause of noninfectious uveitis with a known etiological factor in many high-risk populations, including India, Thailand, and Chile, and a major cause of panuveitis in Tunisia, Iran, Japan, and the Hispanic population in the United States ( Liberman et al, 2015 ; O’keefe and Rao, 2017 ).…”

Section: Vogt–koyanagi–harada Diseasementioning

confidence: 99%

miRNA Landscape in Pathogenesis and Treatment of Vogt–Koyanagi–Harada Disease

Vega-Tapia

Bustamante

Valenzuela

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

miRNAs, one of the members of the noncoding RNA family, are regulators of gene expression in inflammatory and autoimmune diseases. Changes in miRNA pool expression have been associated with differentiation of CD4+ T cells toward an inflammatory phenotype and with loss of self-tolerance in autoimmune diseases. Vogt–Koyanagi–Harada (VKH) disease is a chronic multisystemic pathology, affecting the uvea, inner ear, central nervous system, and skin. Several lines of evidence support an autoimmune etiology for VKH, with loss of tolerance against retinal pigmented epithelium-related self-antigens. This deleterious reaction is characterized by exacerbated inflammation, due to an aberrant TH1 and TH17 polarization and secretion of their proinflammatory hallmark cytokines interleukin 6 (IL-6), IL-17, interferon γ, and tumor necrosis factor α, and an impaired CD4+ CD25high FoxP3+ regulatory T cell function. To restrain inflammation, VKH is pharmacologically treated with corticosteroids and immunosuppressive drugs as first and second line of therapy, respectively. Changes in the expression of miRNAs related to immunoregulatory pathways have been associated with VKH development, whereas some genetic variants of miRNAs have been found to be risk modifiers of VKH. Furthermore, the drugs commonly used in VKH treatment have great influence on miRNA expression, including those miRNAs associated to VKH disease. This relationship between response to therapy and miRNA regulation suggests that these small noncoding molecules might be therapeutic targets for the development of more effective and specific pharmacological therapy for VKH. In this review, we discuss the latest evidence regarding regulation and alteration of miRNA associated with VKH disease and its treatment.

show abstract

Iris abnormalities may influence the efficacy and filtration strategies of Posner–Schlossman syndrome: a retrospective study involving trabeculectomy, ExPRESS and Ahmed valve implants

Sheng

Zhai

Sun

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Iris Manifestations in Inadequately Treated Chronic Recurrent Vogt-Koyanagi-Harada Disease

Cited by 4 publications

References 17 publications

Bilateral Iris depigmentation, transillumination defects and hypotony in Vogt–Koyanagi–Harada disease

Bilateral Iris depigmentation, transillumination defects and hypotony in Vogt–Koyanagi–Harada disease

miRNA Landscape in Pathogenesis and Treatment of Vogt–Koyanagi–Harada Disease

Iris abnormalities may influence the efficacy and filtration strategies of Posner–Schlossman syndrome: a retrospective study involving trabeculectomy, ExPRESS and Ahmed valve implants

Contact Info

Product

Resources

About